Transplant
Conference Coverage
Compound CAR T – a double whammy with promise for AML
For the first time, “a compound CAR with two independent CAR units induced remissions in AML.”
Conference Coverage
Tandem transplantation, long-term maintenance may extend MM remission
Conference Coverage
One-fifth of stem cell transplantation patients develop PTSD
“Clinically significant PTSD symptoms are common in the transplant population.”
Conference Coverage
Risk index stratifies pediatric leukemia patients undergoing HSCT
Conference Coverage
Erythema and sclerosis predict chronic GVHD clinical response, survival
"Our findings highlight the importance of thorough skin exams in chronic GVHD patients."
From the Journals
REACH2: Ruxolitinib outperformed control treatment for refractory acute GVHD
Ruxolitinib was significantly more effective against acute graft-versus-host disease but produced more thrombocytopenia than did control treatment...
From the Journals
CLAM trial regimen shown safe, effective for r/r AML
High response rates and effective bridge to transplant shown.
From the Journals
Cytokine release syndrome in severe COVID-19: Is tocilizumab effective?
Guidelines
COVID-19: ASTCT provides interim guidelines for transplantation
The American Society for Transplantation and Cellular Therapy document focuses on patient-treatment specifics and donor issues.
Conference Coverage
Second transplant a good salvage option for children with ALL, AML, or MDS
From the Journals
NMA haploidentical allo-BMT plus post-transplant cyclophosphamide deemed safe, effective for CLL
Patients with less than 20% marrow CLL involvement before transplant had an improved 4 year survival.